These are the stocks posting the largest moves after the bell on Tuesday, including: Square, Gilead Sciences, Herbalife and more.
CNBC's Meg Tirrell reports on Gilead's earnings conference call, including what CEO John Milligan has to say.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.
U.S. stock index futures pointed to a flat to slightly higher open, as investors prepared for further earnings and more election news.
Jim Cramer rattles off his take on caller favorite stocks, including this healthcare stock standing alone in a tough cohort.
CNBC's Meg Tirrell reports details from Amgen's earnings conference call, including what CEO Robert Bradway has to say. The "Fast Money" traders weigh in on the biotech sector.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
These five names are the cheapest stocks in the market right now. Are they worthy buys at these levels?
Leigh Drogen, Estimize CEO and co-founder, shares his list of Q3 potential earnings beats and misses.
Jim Cramer explained the silver lining of the market going into earnings season.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
The "Fast Money" traders share their first moves for the market open.
The "Fast Money" traders share their final trades of the day including Bank of America, Gilead and more.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 2 stocks with analyst recommendations, including Gilead Sciences and Autozone.
CNBC's Jim Cramer explains why he is watching pharmaceutical names.
The "Fast Money" traders share their final trades of the day including Gilead, Twitter and more.
CNBC's Meg Tirrell reports on what can be the next big biotech takeover. The "Fast Money" traders weigh in.
Biotech stocks were among the top performers in the U.S. stock market Tuesday amid a flurry of merger and product news.
Tobira Therapeutics shares surge after Allergan agrees to buy the drug developer for $1.7. CNBC's Meg Tirrell reports the details, as well as other biotech takeover targets surrounding progressive liver disease "NASH."